127 results on '"Zora R, Rogers"'
Search Results
2. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study
- Author
-
Zora R. Rogers, Taizo A. Nakano, Timothy S. Olson, Alison A. Bertuch, Winfred Wang, Alfred Gillio, Thomas D. Coates, Anjulika Chawla, Paul Castillo, Peter Kurre, Christopher Gamper, Carolyn M. Bennett, Sarita Joshi, Amy E. Geddis, Jessica Boklan, Grzegorz Nalepa, Jennifer A. Rothman, James N. Huang, Gary M. Kupfer, Michaela Cada, Bertil Glader, Kelly J. Walkovich, Alexis A. Thompson, Rabi Hanna, Adrianna Vlachos, Maggie Malsch, Edie A. Weller, David A. Williams, and Akiko Shimamura more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia for pediatric patients is also limited. The clinical features and outcomes for 314 children treated from 2002 to 2014 with immunosuppressive therapy for acquired severe aplastic anemia were analyzed retrospectively from 25 institutions in the North American Pediatric Aplastic Anemia Consortium. The majority of subjects (n=264) received horse anti-thymocyte globulin (hATG) plus cyclosporine (CyA) with a median 61 months follow up. Following hATG/CyA, 71.2% (95%CI: 65.3,76.6) achieved an objective response. In contrast to adult studies, the quality of response achieved in pediatric patients was high, with 59.8% (95%CI: 53.7,65.8) complete response and 68.2% (95%CI: 62.2,73.8) achieving at least a very good partial response with a platelet count ≥50×109L. At five years post-hATG/CyA, overall survival was 93% (95%CI: 89,96), but event-free survival without subsequent treatment was only 64% (95%CI: 57,69) without a plateau. Twelve of 171 evaluable patients (7%) acquired clonal abnormalities after diagnosis after a median 25.2 months (range: 4.3-71 months) post treatment. Myelodysplastic syndrome or leukemia developed in 6 of 314 (1.9%). For relapsed/refractory disease, treatment with a hematopoietic stem cell transplant had a superior event-free survival compared to second immunosuppressive therapy treatment in a multivariate analysis (HR=0.19, 95%CI: 0.08,0.47; P=0.0003). This study highlights the need for improved therapies to achieve sustained high-quality remission for children with severe aplastic anemia. more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline
- Author
-
Trinity J, Bivalacqua, Bryant K, Allen, Gerald B, Brock, Gregory A, Broderick, Roger, Chou, Tobias S, Kohler, John P, Mulhall, Jeff, Oristaglio, Leila L, Rahimi, Zora R, Rogers, Ryan P, Terlecki, Landon, Trost, Faysal A, Yafi, and Nelson E, Bennett more...
- Subjects
Male ,Ischemia ,Penile Erection ,Urology ,Humans ,Anemia, Sickle Cell ,Priapism ,Penis - Abstract
Priapism is a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation and results in a prolonged and uncontrolled erection. Given its time-dependent and progressive nature, priapism is a situation that both urologists and emergency medicine practitioners must be familiar with and comfortable managing.A comprehensive search of the literature on acute ischemic priapism and non-ischemic priapism (NIP) was performed by Emergency Care Research Institute for articles published between January 1, 1960 and May 1, 2020. A search of the literature on NIP, recurrent priapism, prolonged erection following intracavernosal vasoactive medication, and priapism in patients with sickle cell disease was conducted by Pacific Northwest Evidence-based Practice Center for articles published between 1946 and February 19, 2021. Searches identified 4117 potentially relevant articles, and 3437 of these were excluded at the title or abstract level for not meeting inclusion criteria. Full texts for the remaining 680 articles were ordered, and ultimately 203 unique articles were included in the report.This Guideline provides a clinical framework for the treatment (non-surgical and surgical) of NIP, recurrent ischemic priapism, and priapism in patients with sickle cell disease. The treatment of patients with a prolonged erection following intracavernosal vasoactive medication is also included. The AUA guideline on the diagnosis of priapism and the treatment of acute ischemic priapism was published in 2021.All patients with priapism should be evaluated emergently to identify the sub-type of priapism (acute ischemic versus non-ischemic) and those with an acute ischemic event should be provided early intervention when indicated. NIP is not an emergency and treatment must be based on patient objectives, available resources, and clinician experience. Management of recurrent ischemic priapism requires treatment of acute episodes and a focus on future prevention of an acute ischemic event. Sickle cell disease patients presenting with an acute ischemic priapism event should initially be managed with a focus on urologic relief of the erection; standard sickle cell assessment and interventions should be considered concurrent with urologic intervention. Treatment protocols for a prolonged, iatrogenic erection must be differentiated from protocols for true priapism. more...
- Published
- 2022
- Full Text
- View/download PDF
4. Acute Ischemic Priapism: An AUA/SMSNA Guideline
- Author
-
Jeff Oristaglio, Faysal A. Yafi, Ryan Terlecki, Zora R. Rogers, Landon Trost, Gregory A. Broderick, Tobias S. Köhler, Bryant Allen, Gerald B. Brock, John P. Mulhall, Leila L. Rahimi, Nelson E. Bennett, and Trinity J. Bivalacqua more...
- Subjects
Adult ,Male ,Time Factors ,Ischemic priapism ,Urology ,Priapism ,MEDLINE ,urologic and male genital diseases ,Phenylephrine ,Erectile Dysfunction ,Ischemia ,medicine ,Humans ,Sexual stimulation ,Emergency Treatment ,Societies, Medical ,business.industry ,Penile Erection ,musculoskeletal, neural, and ocular physiology ,Ultrasonography, Doppler ,Guideline ,medicine.disease ,Combined Modality Therapy ,Sexual dysfunction ,Erectile dysfunction ,Anesthesia ,Acute Disease ,North America ,medicine.symptom ,business ,Penis ,circulatory and respiratory physiology - Abstract
Priapism is a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation and results in a prolonged and uncontrolled erection. Given its time-dependent and progressive nature, priapism is a situation that both urologists and emergency medicine practitioners must be familiar with and comfortable managing. Acute ischemic priapism, characterized by little or no cavernous blood flow and abnormal cavernous blood gases (ie, hypoxic, hypercarbic, acidotic) represents a medical emergency and may lead to cavernosal fibrosis and subsequent erectile dysfunction.A comprehensive search of the literature was performed by Emergency Care Research Institute for articles published between January 1, 1960 and May 1, 2020. Searches identified 2948 potentially relevant articles, and 2516 of these were excluded at the title or abstract level for not meeting inclusion criteria for any key question. Full texts for the remaining 432 articles were reviewed, and ultimately 137 unique articles were included in the report.This Guideline was developed to inform clinicians on the proper diagnosis and surgical and non-surgical treatment of patients with acute ischemic priapism. This Guideline addresses the role of imaging, adjunctive laboratory testing, early involvement of urologists when presenting to the emergency room, discussion of conservative therapies, enhanced data for patient counseling on risks of erectile dysfunction and surgical complications, specific recommendations on intracavernosal phenylephrine with or without irrigation, the inclusion of novel surgical techniques (eg, tunneling), and early penile prosthesis placement.All patients with priapism should be evaluated emergently to identify the sub-type of priapism (acute ischemic versus non-ischemic) and those with an acute ischemic event should be provided early intervention. Treatment of the acute ischemic patient must be based on patient objectives, available resources, and clinician experience. As such, a single pathway for managing the condition is oversimplified and no longer appropriate. Using a diversified approach, some men may be treated with intracavernosal injections of phenylephrine alone, others with aspiration/irrigation or distal shunting, and some may undergo non-emergent placement of a penile prosthesis. more...
- Published
- 2021
- Full Text
- View/download PDF
5. Evaluation for Bleeding Disorders in Suspected Child Abuse
- Author
-
James, Anderst, Shannon L, Carpenter, Thomas C, Abshire, Emily, Killough, Eneida A, Mendonca, Stephen M, Downs, Cynthia, Wetmore, Carl, Allen, David, Dickens, James, Harper, Zora R, Rogers, Juhi, Jain, Anne, Warwick, Amber, Yates, Jeffrey, Hord, Jeffrey, Lipton, Hope, Wilson, Suzanne, Kirkwood, Suzanne B, Haney, Andrea Gottsegen, Asnes, Amy R, Gavril, Rebecca Greenlee, Girardet, Nancy, Heavilin, Amanda Bird Hoffert, Gilmartin, Antoinette, Laskey, Stephen A, Messner, Bethany Anne, Mohr, Shalon Marie, Nienow, Norell, Rosado, Sheila M, Idzerda, Lori A, Legano, Anish, Raj, Andrew P, Sirotnak, Heather C, Forkey, Brooks, Keeshin, Jennifer, Matjasko, Heather, Edward, Müge, Chavdar, Jorge, Di Paola, Patrick, Leavey, Doug, Graham, Caroline, Hastings, Nobuko, Hijiya, Dana, Matthews, Betty, Pace, Maria C, Velez, Dan, Wechsler, Amy, Billett, Linda, Stork, and Ryan, Hooker more...
- Subjects
Contusions ,Prevalence ,Humans ,Hemorrhage ,Child Abuse ,Blood Coagulation Disorders ,Child - Abstract
Bruising or bleeding in a child can raise the concern for child abuse. Assessing whether the findings are the result of trauma and/or whether the child has a bleeding disorder is critical. Many bleeding disorders are rare, and not every child with bruising/bleeding that may raise a concern for abuse requires an evaluation for bleeding disorders. However, in some instances, bleeding disorders can present in a manner similar to child abuse. Bleeding disorders cannot be ruled out solely on the basis of patient and family history, no matter how extensive. The history and clinical evaluation can be used to determine the necessity of an evaluation for a possible bleeding disorder, and prevalence and known clinical presentations of individual bleeding disorders can be used to guide the extent of laboratory testing. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected. more...
- Published
- 2022
6. Hydroxyurea Dosing in Very Young Children (HUGKISS): Challenges of Study Design
- Author
-
Meghna Dua, Winfred C. Wang, Timothy McCavit, Suvankar Majumdar, R. Clark Brown, Zora R. Rogers, Jeffrey Gossett, Guolian Kang, and Jeremie H. Estepp
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
7. Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)
- Author
-
Meghna Dua, Winfred C. Wang, R. Clark Brown, Melissa A. McNaull, Zora R. Rogers, Martha Barton, Jane Hankins, Jeffrey Gossett, Julie Richardson, Jerlym S. Porter, Guolian Kang, and Jeremie H. Estepp
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
8. Connecting the Dots From Fever of Unknown Origin to Myelodysplastic Syndrome: GATA2 Haploinsufficiency
- Author
-
Brian Reys, Kathryn E. Dickerson, Charles F. Timmons, Amanda S. Evans, Raul Montiel-Esparza, Christian A. Wysocki, and Zora R. Rogers
- Subjects
Adolescent ,GATA2 Deficiency ,Haploinsufficiency ,Bioinformatics ,Fever of Unknown Origin ,Frameshift mutation ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Expressivity (genetics) ,Fever of unknown origin ,Frameshift Mutation ,biology ,business.industry ,GATA2 ,Hematology ,Prognosis ,medicine.disease ,biology.organism_classification ,Pancytopenia ,GATA2 Transcription Factor ,Oncology ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,Nontuberculous mycobacteria ,business ,030215 immunology ,High penetrance - Abstract
Leukemia-predisposing conditions, such as GATA2 haploinsufficiency, are known for their high penetrance and expressivity profiles. These disorders pose a difficult diagnostic challenge to even the most experienced clinician when they first present. We describe the case of a 17-year-old male presenting with features of nontuberculous mycobacterial infection, pulmonary fibrinoid granulomatous vasculitis, and myelodysplasia in the setting of a pathogenic GATA2 frameshift mutation confirmed by next-generation sequencing. The broad differential for GATA2 haploinsufficiency requires prompt recognition of key clinical features and laboratory abnormalities towards directing diagnosis and guiding appropriate and perhaps life-saving therapy. more...
- Published
- 2019
- Full Text
- View/download PDF
9. Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors
- Author
-
Melissa M. Hudson, Smita Bhatia, Jacqueline Casillas, Wendy Landier, Zora R. Rogers, Carl Allen, James Harper, Jeffrey Hord, Juhi Jain, Anne Warwick, Cynthia Wetmore, Amber Yates, Jeffrey Lipton, Hope Wilson, Patrick Leavey, Amy Billett, Jorge DiPaola, Doug Graham, Caroline Hastings, Dana Matthews, Betty Pace, Linda Stork, Maria C. Velez, and Dan Wechsler more...
- Subjects
Gerontology ,Adult ,Male ,Adolescent ,media_common.quotation_subject ,Population ,MEDLINE ,Aftercare ,Subspecialty ,Article ,Young Adult ,Promotion (rank) ,Cancer Survivors ,Intervention (counseling) ,Neoplasms ,Health care ,Medicine ,Humans ,Survivors ,Young adult ,education ,Child ,media_common ,education.field_of_study ,business.industry ,Cancer ,medicine.disease ,Pediatrics, Perinatology and Child Health ,business ,Delivery of Health Care ,Follow-Up Studies - Abstract
Progress in therapy has made survival into adulthood a reality for most children, adolescents, and young adults with a cancer diagnosis today. Notably, this growing population remains vulnerable to a variety of long-term therapy-related sequelae. Systematic ongoing follow-up of these patients is, therefore, important to provide for early detection of and intervention for potentially serious late-onset complications. In addition, health counseling and promotion of healthy lifestyles are important aspects of long-term follow-up care to promote risk reduction for physical and emotional health problems that commonly present during adulthood. Both general and subspecialty health care providers are playing an increasingly important role in the ongoing care of childhood cancer survivors, beyond the routine preventive care, health supervision, and anticipatory guidance provided to all patients. This report is based on the guidelines that have been developed by the Children’s Oncology Group to facilitate comprehensive long-term follow-up of childhood, adolescent, and young adult cancer survivors (www.survivorshipguidelines.org). more...
- Published
- 2021
10. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond Blackfan Anemia Registry
- Author
-
Jason E. Farrar, Anupama Narla, Kelly Walkovich, Helge Hartung, Grzegorz Nalepa, Adrianna Vlachos, Evangelia Atsidaftos, Jeffrey M. Lipton, Mohammad Lutfi Lababidi, Jonathan Bernstein, Ellen Muir, Zora R. Rogers, Thomas W. Loew, Waseem Alhushki, Colin A. Sieff, Bertil Glader, Barbara Gruner, Christine M. Knoll, and Arun R Panigrahi more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Anemia ,medicine.medical_treatment ,Pilot Projects ,Hematopoietic stem cell transplantation ,Short stature ,Gastroenterology ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Leucine ,Internal medicine ,medicine ,Humans ,Blood Transfusion ,Diamond–Blackfan anemia ,Adverse effect ,Child ,Anemia, Diamond-Blackfan ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Hematologic Response ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Erythropoiesis ,Feasibility Studies ,Female ,medicine.symptom ,business ,030215 immunology ,Follow-Up Studies - Abstract
Background Diamond-Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by anemia, short stature, congenital anomalies, and cancer predisposition. Most cases are due to mutations in genes encoding ribosomal proteins (RP) leading to RP haploinsufficiency. Effective treatments for the anemia of DBA include chronic red cell transfusions, long-term corticosteroid therapy, or hematopoietic stem cell transplantation. In a small patient series and in animal models, there have been hematologic responses to L-leucine with amelioration of anemia. The study objectives of this clinical trial were to determine feasibility, safety, and efficacy of L-leucine in transfusion-dependent patients with DBA. Procedure Patients ≥2 years of age received L-leucine 700 mg/m2 orally three times daily for nine months to determine a hematologic response and any improvement in growth (NCT01362595). Results This multicenter, phase I/II study enrolled 55 subjects; 43 were evaluable. There were 21 males; the median age at enrollment was 10.4 years (range, 2.5-46.1 years). No significant adverse events were attributable to L-leucine. Two subjects had a complete erythroid response and five had a partial response. Nine of 25, and 11 of 25, subjects experienced a positive weight and height percentile change, respectively, at the end of therapy. Conclusions L-leucine is safe, resulted in an erythroid response in 16% of subjects with DBA, and led to an increase in weight and linear growth velocity in 36% and 44% of evaluable subjects, respectively. Further studies will be critical to understand the role of L-leucine in the management of patients with DBA. more...
- Published
- 2020
11. Real-World Experience Measurement of Liver Iron Concentration by R2 vs. R2 Star MRI in Hemoglobinopathies
- Author
-
Amanda Potersnak, Lubaina Ehsan, Barbara Burkhardt, Gerald F. Greil, Tarique Hussain, Jeanne Dillenbeck, Zora R. Rogers, Riad Abou Zahr, University of Zurich, and Abou Zahr, Riad
- Subjects
Liver Iron Concentration ,T2 star ,Thalassemia ,Sedation ,Clinical Biochemistry ,Population ,610 Medicine & health ,1308 Clinical Biochemistry ,Article ,030218 nuclear medicine & medical imaging ,Scan time ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,liver iron concentration ,education ,education.field_of_study ,lcsh:R5-920 ,business.industry ,Liver Scan ,medicine.disease ,R2 ,Sickle cell anemia ,10036 Medical Clinic ,030220 oncology & carcinogenesis ,R2 star ,Signal averaging ,medicine.symptom ,business ,Nuclear medicine ,lcsh:Medicine (General) ,MRI - Abstract
Background: Non-invasive determination of liver iron concentration (LIC) is a valuable tool that guides iron chelation therapy in transfusion-dependent patients. Multiple methods have been utilized to measure LIC by MRI. The purpose of this study was to compare free breathing R2* (1/T2*) to whole-liver Ferriscan R2 method for estimation of LIC in a pediatric and young adult population who predominantly have hemoglobinopathies. Methods: Clinical liver and cardiac MRI scans from April 2016 to May 2018 on a Phillips 1.5 T scanner were reviewed. Free breathing T2 and T2* weighted images were acquired on each patient. For T2, multi-slice spin echo sequences were obtained. For T2*, a single mid-liver slice fast gradient echo was performed starting at 0.6 ms with 1.2 ms increments with signal averaging. R2 measurements were performed by Ferriscan analysis. R2* measurements were performed by quantitative T2* map analysis. Results: 107 patients underwent liver scans with the following diagnoses: 76 sickle cell anemia, 20 Thalassemia, 9 malignancies and 2 Blackfan Diamond anemia. Mean age was 12.5 ± 4.5 years. Average scan time for R2 sequences was 10 min, while R2* sequence time was 20 s. R2* estimation of LIC correlated closely with R2 with a correlation coefficient of 0.94. Agreement was strongest for LIC < 15 mg Fe/g dry weight. Overall bias from Bland–Altman plot was 0.66 with a standard deviation of 2.8 and 95% limits of agreement −4.8 to 6.1. Conclusion: LIC estimation by R2* correlates well with R2-Ferriscan in the pediatric age group. Due to the very short scan time of R2*, it allows imaging without sedation or anesthesia. Cardiac involvement was uncommon in this cohort. more...
- Published
- 2020
12. Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis
- Author
-
Marya Obaid Almansoori, Kejian Zhang, Karol Kerr, Theodosia A. Kalfa, Omar Niss, Neha Dagaonkar, Maa Ohui Quarmyne, Satheesh Chonat, Zora R. Rogers, Mary Risinger, and Patrick T. McGann
- Subjects
Male ,0301 basic medicine ,Hemolytic anemia ,Adolescent ,Pyropoikilocytosis ,Hereditary elliptocytosis ,DNA Mutational Analysis ,Biology ,medicine.disease_cause ,Article ,03 medical and health sciences ,Elliptocytosis ,0302 clinical medicine ,Genotype ,medicine ,Humans ,Child ,Medical History Taking ,Molecular Biology ,Genetic Association Studies ,Genetics ,Mutation ,Erythrocyte Membrane ,Elliptocytosis, Hereditary ,Infant ,Membrane Proteins ,Spectrin ,EPB41 ,Cell Biology ,Hematology ,medicine.disease ,Pedigree ,Cytoskeletal Proteins ,030104 developmental biology ,Child, Preschool ,030220 oncology & carcinogenesis ,Immunology ,Molecular Medicine ,Female ,Hereditary pyropoikilocytosis - Abstract
Hereditary elliptocytosis (HE) and hereditary pyropoikilocytosis (HPP) are heterogeneous red blood cell (RBC) membrane disorders that result from mutations in the genes encoding α-spectrin (SPTA1), β-spectrin (SPTB), or protein 4.1R (EPB41). The resulting defects alter the horizontal cytoskeletal associations and affect RBC membrane stability and deformability causing shortened RBC survival. The clinical diagnosis of HE and HPP relies on identifying characteristic RBC morphology on peripheral blood smear and specific membrane biomechanical properties using osmotic gradient ektacytometry. However, this phenotypic diagnosis may not be readily available in patients requiring frequent transfusions, and does not predict disease course or severity. Using Next-Generation sequencing, we identified the causative genetic mutations in fifteen patients with clinically suspected HE or HPP and correlated the identified mutations with the clinical phenotype and ektacytometry profile. In addition to identifying three novel mutations, gene sequencing confirmed and, when the RBC morphology was not evaluable, identified the diagnosis. Moreover, genotypic differences justified the phenotypic differences within families with HE/HPP. more...
- Published
- 2016
- Full Text
- View/download PDF
13. Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report
- Author
-
Cindy Neunert, Rabia Saleem, Zora R. Rogers, and James N. George
- Subjects
medicine.medical_specialty ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Immunology ,Splenectomy ,Thrombotic thrombocytopenic purpura ,Follicular lymphoma ,Immunosuppression ,Hematology ,030204 cardiovascular system & hematology ,medicine.disease ,Bethesda unit ,Gastroenterology ,ADAMTS13 ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,Immunology and Allergy ,Medicine ,Rituximab ,business ,medicine.drug - Abstract
Background Appropriate management to prevent relapses of acquired, autoimmune thrombotic thrombocytopenic purpura (TTP) is not clear. Rituximab (375 mg/m2 /week × 4) is effective treatment for acute episodes but it is not consistently effective for prevention of relapses. Maintenance rituximab, 375 mg/m2 /3 months for 2 years, is commonly used to prevent progression of follicular lymphoma, but the outcome of maintenance rituximab to prevent TTP relapses has been rarely reported. Case report An 8-year-old girl was diagnosed with acquired TTP in 2008; her ADAMTS13 activity was less than 5%, with a functional inhibitor of greater than 8 Bethesda units/mL. She achieved remission with therapeutic plasma exchange, corticosteroids, and rituximab (375 mg/m2 /week × 4). During the following 6 years she had seven additional episodes. Each episode responded to therapeutic plasma exchange, sometimes requiring additional treatments (corticosteroids, rituximab, and cyclophosphamide). However, these treatments, as well as splenectomy and trials of cyclophosphamide and mycophenolate mofetil during clinical remissions, failed to prevent relapses. Her ADAMTS13 activity remained 8% or less throughout all of her remissions. Maintenance rituximab was begun in 2013: 500 mg (313 mg/m2 ) every 2-3 months × 5, then 600 mg (375 mg/m2 ) every 6 months × 2. After 1 year, her ADAMTS13 was 26%; after 2 years, 51%. During the past 3 years since stopping rituximab, she has remained well, with normal ADAMTS13 activity (70%-78%). Conclusion Maintenance rituximab treatment may be effective for prevention of relapses in patients with acquired, autoimmune TTP, even when splenectomy and intensive immunosuppression, including multiple conventional courses of rituximab, fail to prevent subsequent relapses. more...
- Published
- 2018
- Full Text
- View/download PDF
14. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
- Author
-
Janet L. Kwiatkowski, Lori Luchtman-Jones, Linda B. Piller, Jennifer A. Rothman, Abdullah Kutlar, R. Clark Brown, Theodosia A. Kalfa, Carla W. Roberts, William H. Schultz, Nicole A. Mortier, Robert J. Adams, Alexis A. Thompson, William Owen, Beng Fuh, Margaret T. Lee, Jamie L. Coleman, Judy Luden, Alex George, Donna R. Roberts, John C. Wood, Kerri Nottage, Ofelia A. Alvarez, Sharada A. Sarnaik, Melanie J. Bonner, Susan E. Stuber, Lee Hilliard, Hamayun Imran, Stephen C. Nelson, Sherron M. Jackson, Sara L. Pressel, Banu Aygun, Matthew M. Heeney, Melissa Rhodes, Connie M. Piccone, Naomi L.C. Luban, Zora R. Rogers, Scott T. Miller, Peng Wei, Kathleen J. Helton, Cynthia Gauger, Isaac Odame, Barry R. Davis, Russell E. Ware, Alan R. Cohen, and Niren Patel more...
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Blood transfusion ,Adolescent ,Ultrasonography, Doppler, Transcranial ,Anemia ,medicine.medical_treatment ,Population ,sickle cell anaemia ,Anemia, Sickle Cell ,Transient ischaemic attacks ,Article ,transcranial Doppler ,law.invention ,Hydroxycarbamide ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Antisickling Agents ,law ,medicine ,Humans ,Hydroxyurea ,Blood Transfusion ,Child ,education ,education.field_of_study ,Drug Substitution ,business.industry ,Standard treatment ,General Medicine ,medicine.disease ,Interim analysis ,Combined Modality Therapy ,3. Good health ,Stroke ,Treatment Outcome ,Cerebrovascular Circulation ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,business ,Blood Flow Velocity ,030215 immunology ,medicine.drug - Abstract
Summary Background For children with sickle cell anaemia and high transcranial doppler (TCD) flow velocities, regular blood transfusions can effectively prevent primary stroke, but must be continued indefinitely. The efficacy of hydroxycarbamide (hydroxyurea) in this setting is unknown; we performed the TWiTCH trial to compare hydroxyurea with standard transfusions. Methods TWiTCH was a multicentre, phase 3, randomised, open-label, non-inferiority trial done at 26 paediatric hospitals and health centres in the USA and Canada. We enrolled children with sickle cell anaemia who were aged 4–16 years and had abnormal TCD flow velocities (≥200 cm/s) but no severe vasculopathy. After screening, eligible participants were randomly assigned 1:1 to continue standard transfusions (standard group) or hydroxycarbamide (alternative group). Randomisation was done at a central site, stratified by site with a block size of four, and an adaptive randomisation scheme was used to balance the covariates of baseline age and TCD velocity. The study was open-label, but TCD examinations were read centrally by observers masked to treatment assignment and previous TCD results. Participants assigned to standard treatment continued to receive monthly transfusions to maintain 30% sickle haemoglobin or lower, while those assigned to the alternative treatment started oral hydroxycarbamide at 20 mg/kg per day, which was escalated to each participant's maximum tolerated dose. The treatment period lasted 24 months from randomisation. The primary study endpoint was the 24 month TCD velocity calculated from a general linear mixed model, with the non-inferiority margin set at 15 cm/s. The primary analysis was done in the intention-to-treat population and safety was assessed in all patients who received at least one dose of assigned treatment. This study is registered with ClinicalTrials.gov, number NCT01425307. Findings Between Sept 20, 2011, and April 17, 2013, 159 patients consented and enrolled in TWiTCH. 121 participants passed screening and were then randomly assigned to treatment (61 to transfusions and 60 to hydroxycarbamide). At the first scheduled interim analysis, non-inferiority was shown and the sponsor terminated the study. Final model-based TCD velocities were 143 cm/s (95% CI 140–146) in children who received standard transfusions and 138 cm/s (135–142) in those who received hydroxycarbamide, with a difference of 4·54 (0·10–8·98). Non-inferiority (p=8·82 × 10 −16 ) and post-hoc superiority (p=0·023) were met. Of 29 new neurological events adjudicated centrally by masked reviewers, no strokes were identified, but three transient ischaemic attacks occurred in each group. Magnetic resonance brain imaging and angiography (MRI and MRA) at exit showed no new cerebral infarcts in either treatment group, but worsened vasculopathy in one participant who received standard transfusions. 23 severe adverse events in nine (15%) patients were reported for hydroxycarbamide and ten serious adverse events in six (10%) patients were reported for standard transfusions. The most common serious adverse event in both groups was vaso-occlusive pain (11 events in five [8%] patients with hydroxycarbamide and three events in one [2%] patient for transfusions). Interpretation For high-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocities and help to prevent primary stroke. Funding National Heart, Lung, and Blood Institute, National Institutes of Health. more...
- Published
- 2016
- Full Text
- View/download PDF
15. Effects of hydroxyurea treatment for patients with hemoglobin SC disease
- Author
-
Margaret T. Lee, Zora R. Rogers, Theodosia A. Kalfa, Russell E. Ware, Banu Aygun, Kathryn L. Hassell, Courtney D. Thornburg, Janet L. Kwiatkowski, William Owen, Carla W. Roberts, Hamayun Imran, Mary G. Smith, Lee Hilliard, Alexis A. Thompson, Barry R. Davis, R. Clark Brown, Lori Luchtman-Jones, Sara L. Pressel, Cynthia Gauger, Connie M. Piccone, Ofelia A. Alvarez, Jennifer A. Rothman, and Stephen C. Nelson more...
- Subjects
Pediatrics ,medicine.medical_specialty ,Hemoglobin SC Disease ,medicine.diagnostic_test ,Anemia ,business.industry ,Thalassemia ,Hematology ,Neutropenia ,medicine.disease ,Acute chest syndrome ,Sickle cell anemia ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,medicine ,Absolute neutrophil count ,business ,Mean corpuscular volume ,030215 immunology - Abstract
Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA), which includes HbSS and HbS/β(0) -thalassemia genotypes, many patients with HbSC experience severe disease complications, including vaso-occlusive pain, acute chest syndrome, avascular necrosis, retinopathy, and poor quality of life. Fully 20 years after the clinical and laboratory efficacy of hydroxyurea was proven in adult SCA patients, the safety and utility of hydroxyurea treatment for HbSC patients remain unclear. Recent NHLBI evidence-based guidelines highlight this as a critical knowledge gap, noting HbSC accounts for ∼30% of sickle cell patients within the United States. To date, only 5 publications have reported short-term, incomplete, or conflicting laboratory and clinical outcomes of hydroxyurea treatment in a total of 71 adults and children with HbSC. We now report on a cohort of 133 adult and pediatric HbSC patients who received hydroxyurea, typically for recurrent vaso-occlusive pain. Hydroxyurea treatment was associated with a stable hemoglobin concentration; increased fetal hemoglobin (HbF) and mean corpuscular volume (MCV); and reduced white blood cell count (WBC), absolute neutrophil count (ANC), and absolute reticulocyte count (ARC). Reversible cytopenias occurred in 22% of patients, primarily neutropenia and thrombocytopenia. Painful events were reduced with hydroxyurea, more in patients >15 years old. These multicenter data support the safety and potentially salutary effects of hydroxyurea treatment for HbSC disease; however, a multicenter, placebo-controlled, Phase 3 clinical trial is needed to determine if hydroxyurea therapy has efficacy for patients with HbSC disease. more...
- Published
- 2016
- Full Text
- View/download PDF
16. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial
- Author
-
Connie M. Piccone, Zora R. Rogers, John C. Wood, William Owen, Hamayun Imran, Beng Fuh, Carla W. Roberts, William H. Schultz, Sherron M. Jackson, Beatrice E. Gee, Sharada A. Sarnaik, Russell E. Ware, Theodosia A. Kalfa, Lori Luchtman-Jones, Ofelia A. Alvarez, Alex George, Kerri Nottage, Jennifer Webb, Elizabeth Yang, Jane S. Hankins, R. Clark Brown, Sharon A. Singh, Isaac Odame, Barry R. Davis, Lee Hilliard, Kim Smith Whitley, Melissa Rhodes, Cynthia Gauger, Scott T. Miller, Alan R. Cohen, Janet L. Kwiatkowski, Sara L. Pressel, Alexis A. Thompson, Matthew M. Heeney, Jennifer A. Rothman, Margaret T. Lee, Banu Aygun, Brigitta U. Mueller, and Stephen C. Nelson more...
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Liver Iron Concentration ,Iron Overload ,Blood transfusion ,Ultrasonography, Doppler, Transcranial ,Iron ,medicine.medical_treatment ,Anemia, Sickle Cell ,Iron Chelating Agents ,Kidney ,Gastroenterology ,Article ,Hydroxycarbamide ,03 medical and health sciences ,0302 clinical medicine ,Antisickling Agents ,Internal medicine ,medicine ,Humans ,Hydroxyurea ,Child ,Pancreas ,chemistry.chemical_classification ,business.industry ,Transfusion Reaction ,Hematology ,medicine.disease ,Magnetic Resonance Imaging ,Stroke ,medicine.anatomical_structure ,Liver ,chemistry ,Transferrin ,030220 oncology & carcinogenesis ,Ferritins ,Toxicity ,Female ,Transfusion therapy ,business ,Reperfusion injury ,Spleen ,030215 immunology ,medicine.drug - Abstract
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell anaemia (SCA) and abnormal TCD. Severity and location of iron overload is an important secondary outcome measure. We report the baseline findings of abdominal organ iron burden in 121 participants. At enrollment, patients were young (9·8 ± 2·9 years), predominantly female (60:40), and previously treated with transfusions (4·1 ± 2·4 years) and iron chelation (3·1 ± 2·1 years). Liver iron concentration (LIC; 9·0 ± 6·6 mg/g dry weight) and serum ferritin were moderately elevated (2696 ± 1678 μg/l), but transferrin was incompletely saturated (47·2 ± 23·6%). Spleen R2* was 509 ± 399 Hz (splenic iron ~13·9 mg/g) and correlated with LIC (r(2) = 0·14, P = 0·0008). Pancreas R2* was increased in 38·3% of patients but not to levels associated with endocrine toxicity. Kidney R2* was increased in 80·7% of patients; renal iron correlated with markers of intravascular haemolysis and was elevated in patients with increased urine albumin-creatinine ratios. Extra-hepatic iron deposition is common among children with SCA who receive chronic transfusions, and could potentiate oxidative stress caused by reperfusion injury and decellularized haemoglobin. more...
- Published
- 2015
- Full Text
- View/download PDF
17. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia
- Author
-
Jeremie H. Estepp, Jennifer A. Rothman, Andrew Lewandowski, Chiara Melloni, Paweł Wiczling, Courtney D. Thornburg, Uttam Garg, William J. Jusko, Zora R. Rogers, Shelley E. Crary, Kathleen A. Neville, Maurine H. Morris, Amanda M. Brandow, Nancy S. Green, Robert I. Liem, and Thomas H. Howard more...
- Subjects
Male ,Drug ,medicine.medical_specialty ,Adolescent ,media_common.quotation_subject ,Thalassemia ,Population ,Capsules ,Anemia, Sickle Cell ,Pharmacology ,Bioequivalence ,Article ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Antisickling Agents ,Internal medicine ,medicine ,Humans ,Hydroxyurea ,Pharmacology (medical) ,Prospective Studies ,Dosing ,Child ,education ,Prospective cohort study ,media_common ,education.field_of_study ,business.industry ,medicine.disease ,Sickle cell anemia ,Solutions ,Therapeutic Equivalency ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology - Abstract
Hydroxyurea (HU) is a crucial therapy for children with sickle cell anemia, but its off-label use is a barrier to widespread acceptance. We found HU exposure is not significantly altered by liquid vs capsule formulation, and weight-based dosing schemes provide consistent exposure. HU is recommended for all children starting as young as 9 months of age with sickle cell anemia (SCA; HbSS and HbSβspan(0) thalassemia); however; a paucity of pediatric data exists regarding the pharmacokinetics (PK) or the exposure-response relationship of HU. This trial aimed to characterize the PK of HU in children and to evaluate and compare the bioavailability of a liquid vs capsule formulation. This multicenter; prospective; open-label trial enrolled 39 children with SCA who provided 682 plasma samples for PK analysis following administration of HU. Noncompartmental and population PK models are described. We report that liquid and capsule formulations of HU are bioequivalent; weight-based dosing schemes provide consistent drug exposure; and age-based dosing schemes are unnecessary. These data support the use of liquid HU in children unable to swallow capsules and in those whose weight precludes the use of fixed capsule formulations. Taken with existing safety and efficacy literature; these findings should encourage the use of HU across the spectrum of age and weight in children with SCA; and they should facilitate the expanded use of HU as recommended in the National Heart; Lung; and Blood Institute guidelines for individuals with SCA. more...
- Published
- 2015
- Full Text
- View/download PDF
18. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial
- Author
-
William H. Schultz, John C. Wood, Russell E. Ware, Janet L. Kwiatkowski, William Owen, Zora R. Rogers, Margaret T. Lee, Sara L. Pressel, Matthew M. Heeney, Alan R. Cohen, Isaac Odame, Barry R. Davis, and Timothy G. St. Pierre more...
- Subjects
medicine.medical_specialty ,Liver Iron Concentration ,Blood transfusion ,medicine.diagnostic_test ,business.industry ,Anemia ,medicine.medical_treatment ,Deferasirox ,Magnetic resonance imaging ,Hematology ,medicine.disease ,Sickle cell anemia ,Surgery ,Clinical trial ,medicine ,Nuclear medicine ,business ,Stroke ,medicine.drug - Abstract
Noninvasive, quantitative, and accurate assessment of liver iron concentration (LIC) by MRI is useful for patients receiving transfusions, but R2 and R2* MRI techniques have not been systematically compared in sickle cell anemia (SCA). We report baseline LIC results from the TWiTCH trial, which compares hydroxyurea with blood transfusion treatment for primary stroke prophylaxis assessed by transcranial Doppler sonography in pediatric SCA patients. Liver R2 was collected and processed using a FDA-approved commercial process (FerriScan®), while liver R2* quality control and processing were performed by a Core Laboratory blinded to clinical site and patient data. Baseline LIC studies using both MRI techniques were available for 120 participants. LICR2* and LICR2 results were highly correlated (r2 = 0.93). A proportional bias of LIC(R2*)/LIC(R2), decreasing with average LIC, was observed. Systematic differences between LICR2* and LICR2 were also observed by MRI manufacturer. Importantly, LICR2* and LICR2 estimates had broad 95% limits of agreement with respect to each other. We recommend LICR2 and LICR2* not be used interchangeably in SCA patients to follow individual patient trends in iron burden.Am. J. Hematol. 90:806–810, 2015. © 2015 Wiley Periodicals, Inc. more...
- Published
- 2015
- Full Text
- View/download PDF
19. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload
- Author
-
Russell E. Ware, Pamela B. Sylvestre, Scott T. Miller, Karen Kesler, Zora R. Rogers, Peter A. Lane, Janet L. Kwiatkowski, William H. Schultz, Banu Aygun, Nicole A. Mortier, Alan R. Cohen, Alexandre Lockhart, Rathi V. Iyer, and Ofelia A. Alvarez more...
- Subjects
Male ,Liver Iron Concentration ,Pediatrics ,medicine.medical_specialty ,Iron Overload ,Blood transfusion ,Adolescent ,Iron ,medicine.medical_treatment ,Anemia, Sickle Cell ,Article ,Hydroxycarbamide ,Young Adult ,Phlebotomy ,medicine ,Humans ,Young adult ,Child ,Adverse effect ,Stroke ,biology ,business.industry ,Transfusion Reaction ,Hematology ,medicine.disease ,Ferritin ,Treatment Outcome ,Liver ,Child, Preschool ,Ferritins ,biology.protein ,Female ,business ,medicine.drug - Abstract
Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse events, all of which were grade 2. Among 23 children completing 30 months of study treatment, the net iron balance was favourable (-8·7 mg Fe/kg) with significant decrease in ferritin, although liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well-tolerated, with net iron removal in most children who completed 30 months of protocol-directed treatment. more...
- Published
- 2015
- Full Text
- View/download PDF
20. Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): An initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC)
- Author
-
Jeffrey M. Lipton, David A. Williams, Kelly Walkovich, Seth J. Corey, Zora R. Rogers, Akiko Shimamura, Winfred C. Wang, Colin A. Sieff, Thomas D. Coates, Yigal Dror, Adrianna Vlachos, James N. Huang, Alison B. Bertuch, Ulrike M. Reiss, Monica Bessler, Carolyn M. Bennett, and Timothy S. Olson more...
- Subjects
medicine.medical_specialty ,Pediatrics ,Hematology ,business.industry ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,medicine.disease ,law.invention ,Transplantation ,medicine.anatomical_structure ,Oncology ,Randomized controlled trial ,law ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Epidemiology ,medicine ,Bone marrow ,Aplastic anemia ,business ,Rare disease - Abstract
Background Randomized clinical trials in pediatric aplastic anemia (AA) are rare and data to guide standards of care are scarce. Procedure Eighteen pediatric institutions formed the North American Pediatric Aplastic Anemia Consortium to foster collaborative studies in AA. The initial goal of NAPAAC was to survey the diagnostic studies and therapies utilized in AA. Results Our survey indicates considerable variability among institutions in the diagnosis and treatment of AA. There were areas of general consensus, including the need for a bone marrow evaluation, cytogenetic and specific fluorescent in situ hybridization assays to establish diagnosis and exclude genetic etiologies with many institutions requiring results prior to initiation of immunosuppressive therapy (IST); uniform referral for hematopoietic stem cell transplantation as first line therapy if an HLA-identical sibling is identified; the use of first-line IST containing horse anti-thymocyte globulin and cyclosporine A (CSA) if an HLA-identical sibling donor is not identified; supportive care measures; and slow taper of CSA after response. Areas of controversy included the need for telomere length results prior to IST, the time after IST initiation defining a treatment failure; use of hematopoietic growth factors; the preferred rescue therapy after failure of IST; the use of specific hemoglobin and platelet levels as triggers for transfusion support; the use of prophylactic antibiotics; and follow-up monitoring after completion of treatment. Conclusions These initial survey results reflect heterogeneity in diagnosis and care amongst pediatric centers and emphasize the need to develop evidence-based diagnosis and treatment approaches in this rare disease. Pediatr Blood Cancer 2014;61:869–874. © 2013 Wiley Periodicals, Inc. more...
- Published
- 2013
- Full Text
- View/download PDF
21. Evaluation for Bleeding Disorders in Suspected Child Abuse
- Author
-
Brigitta U. Mueller, John M. Leventhal, Emalee G. Flaherty, Eric J. Werner, Cindy W. Christian, Thomas C. Abshire, James L. Lukefahr, Jeffrey D. Hord, Shannon L. Carpenter, James E. Crawford-Jakubiak, Robert Sege, Gary Crouch, Patricia Shearer, Gregory Hale, James D. Anderst, and Zora R. Rogers more...
- Subjects
Child abuse ,medicine.medical_specialty ,Contusions ,Poison control ,Hemorrhage ,Hemorrhagic Disorders ,Suicide prevention ,Occupational safety and health ,Decision Support Techniques ,Diagnosis, Differential ,Injury prevention ,medicine ,Humans ,Child Abuse ,Child ,Intensive care medicine ,business.industry ,Infant, Newborn ,Infant ,food and beverages ,Human factors and ergonomics ,Blood Coagulation Disorders ,Vitamin K Deficiency Bleeding ,medicine.disease ,Bleeding diathesis ,Suspected child abuse ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Blood Coagulation Tests ,Medical emergency ,business ,Intracranial Hemorrhages - Abstract
Bruising or bleeding in a child can raise the concern for child abuse. Assessing whether the findings are the result of trauma and/or whether the child has a bleeding disorder is critical. Many bleeding disorders are rare, and not every child with bruising/bleeding concerning for abuse requires an evaluation for bleeding disorders. In some instances, however, bleeding disorders can present in a manner similar to child abuse. The history and clinical evaluation can be used to determine the necessity of an evaluation for a possible bleeding disorder, and prevalence and known clinical presentations of individual bleeding disorders can be used to guide the extent of the laboratory testing. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected. more...
- Published
- 2013
- Full Text
- View/download PDF
22. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study
- Author
-
Zora R. Rogers, James F. Casella, Ming Lu, R. Clark Brown, Sharada A. Sarnaik, Rathi V. Iyer, Winfred C. Wang, Scott T. Miller, Thomas H. Howard, and Jeffrey D. Lebensburger
- Subjects
Pediatrics ,medicine.medical_specialty ,Fever ,Anemia ,Pain ,Anemia, Sickle Cell ,Kidney ,Placebo ,Article ,law.invention ,Hemoglobins ,Double-Blind Method ,Thoracic Diseases ,Randomized controlled trial ,Antisickling Agents ,law ,Humans ,Hydroxyurea ,Medicine ,business.industry ,Incidence (epidemiology) ,Infant ,Hematology ,medicine.disease ,Acute chest syndrome ,Sickle cell anemia ,Clinical trial ,Oncology ,Acute Disease ,Pediatrics, Perinatology and Child Health ,Hemoglobin ,business ,Spleen - Abstract
Background Clinical complications of sickle cell anemia begin in infancy. BABY HUG (ClinicalTrials.gov, NCT00006400) was a NHLBI-NICHD supported randomized phase III placebo-controlled trial of hydroxyurea (HU) in infants (recruited at 9–18 months) unselected for clinical severity with sickle cell anemia. This secondary analysis of data from BABY HUG examines the influence of anemia on the incidence of sickle cell related complications, and the impact of hydroxyurea therapy in altering these events by comparing children with lower ( 75th percentile) hemoglobin concentrations at study entry. Procedure Infants were categorized by: (1) age-adjusted hemoglobin quartiles as determined by higher (Hi) and lower (Lo) hemoglobin concentrations at study entry (9–12 months old: 10.0 gm/dL; 12–18 months old: 9.9 gm/dL) and (2) treatment arm (hydroxyurea or placebo). Four subgroups were created: placebo (PL) LoHb (n = 25), PL HiHb (n = 27), hydroxyurea (HU) LoHb (n = 21), and HU HiHb (n = 18). The primary and secondary endpoints of BABY HUG were analyzed by subgroup. Results Infants with lower hemoglobin at baseline were more likely to have a higher incidence of clinical events (acute chest syndrome, pain crisis, fever) as well as higher TCD velocities and lower neuropsychological scores at study exit. Hydroxyurea reduced the incidence of these findings. Conclusion Infants with more severe anemia are at risk for increased clinical events that may be prevented by early initiation of hydroxyurea. Pediatr Blood Cancer 2012;59:675–678. © 2011 Wiley Periodicals, Inc. more...
- Published
- 2011
- Full Text
- View/download PDF
23. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload
- Author
-
Ronald W. Helms, Rathi V. Iyer, Zora R. Rogers, Scott T. Miller, Russell E. Ware, Nicole A. Mortier, Myron A. Waclawiw, Lee Hilliard, William H. Schultz, Nancy A. Yovetich, J. Paul Scott, and Ofelia A. Alvarez more...
- Subjects
Pediatrics ,medicine.medical_specialty ,Anemia ,business.industry ,Hematology ,medicine.disease ,Sickle cell anemia ,law.invention ,Clinical trial ,Oncology ,Randomized controlled trial ,law ,Recurrent stroke ,Pediatrics, Perinatology and Child Health ,medicine ,Chelation therapy ,Young adult ,business ,Stroke - Abstract
Background Stroke occurs in 5–10% of children with sickle cell anemia (SCA) and has a high (>50%) risk of recurrence without therapy. Chronic monthly erythrocyte transfusions effectively prevent recurrent stroke, but their long term use is limited by serious side effects, including iron overload. An alternative to transfusion for secondary stroke prevention in SCA is needed, especially one that also improves the management of iron overload. more...
- Published
- 2011
- Full Text
- View/download PDF
24. Abdominal Ultrasound With Scintigraphic and Clinical Correlates in Infants With Sickle Cell Anemia: Baseline Data From the BABY HUG Trial
- Author
-
Zora R. Rogers, Renee C. Rees, Scott T. Miller, Zhaoyu Luo, M. Beth McCarville, Ram Kalpatthi, Winfred C. Wang, Xiangke Huang, and Bruce W. Thompson
- Subjects
Male ,Hemolytic anemia ,medicine.medical_specialty ,Anemia ,Urinary system ,Anemia, Sickle Cell ,Kidney ,Article ,law.invention ,Placebos ,Randomized controlled trial ,Antisickling Agents ,law ,Internal medicine ,Abdomen ,Humans ,Hydroxyurea ,Medicine ,Radiology, Nuclear Medicine and imaging ,Radionuclide Imaging ,Ultrasonography ,Analysis of Variance ,business.industry ,Gallbladder ,Infant ,Alanine Transaminase ,Bilirubin ,General Medicine ,medicine.disease ,Institutional review board ,Sickle cell anemia ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,Technetium Tc 99m Sulfur Colloid ,Female ,business ,Spleen ,Glomerular Filtration Rate - Abstract
The purpose of this study is to perform and evaluate baseline abdominal ultrasound in infants with sickle cell anemia who participated in the BABY HUG multiinstitutional randomized placebo-controlled trial of hydroxyurea therapy and to examine the potential relationships among ultrasound results and clinical, nuclear medicine, and laboratory data.After local institutional review board approval and with informed guardian consent, 116 girls and 87 boys (age range, 7.5-18 months) with sickle cell anemia underwent standardized abdominal sonography at 14 institutions. Imaging was centrally reviewed by one radiologist who assessed and measured the spleen, kidneys, gallbladder, and common bile duct. Baseline physical assessment of spleen size, serum alanine aminotransferase and bilirubin levels, (99m)Tc sulfur colloid liver-spleen scans, and (99m)Tc diethylenetriaminepentaacetic acid clearance glomerular filtration rates (GFRs) were obtained. Analysis of variance and the Student test were performed to compare sonographic findings to published results in healthy children and to clinical and laboratory findings.The mean (± SD) spleen volume (108 ± 47 mL) was significantly greater than published normal control values (30 ± 14 mL; p0.0001). There was no correlation between spleen volume and function assessed by liver-spleen scan. The mean GFR (125 ± 34 mL/min/1.73 m(2)) was elevated compared with control GFRs (92 ± 18 mL/min/1.73 m(2)). Renal volumes (right kidney, 29 ± 8 mL; left kidney, 31 ± 9 mL) were significantly greater than control volumes (right kidney, 27 ± 3 mL; left kidney, 27 ± 3 mL; p0.0001) and were positively correlated with GFR (p = 0.0009). Five percent of patients had sonographic biliary abnormalities (sludge, n = 6; dilated common bile duct, n = 2; and cholelithiasis and thickened gallbladder wall, n = 1 each). There was no correlation between biliary sonographic findings and laboratory results.In infants with sickle cell anemia, sonographic spleen volume does not reflect function, but increased renal volume correlates with GFR and is consistent with hyperfiltration. Sonographic biliary abnormalities can occur early in life, while remaining clinically silent. more...
- Published
- 2011
- Full Text
- View/download PDF
25. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial
- Author
-
Scott T. Miller, Rathi V. Iyer, Russell E. Ware, Zora R. Rogers, Bea Files, Barry L. Shulkin, John H. Miller, Eglal Shalaby-Rana, Winfred C. Wang, Bruce W. Thompson, Zhaoyu Luo, Peter A. Lane, and Stephen D. Dertinger more...
- Subjects
Male ,Hemolytic anemia ,medicine.medical_specialty ,Pathology ,Clinical Trials and Observations ,Anemia ,Immunology ,Spleen ,Anemia, Sickle Cell ,Biochemistry ,Gastroenterology ,White blood cell ,Internal medicine ,Fetal hemoglobin ,medicine ,Humans ,Hematology ,business.industry ,Infant ,Cell Biology ,medicine.disease ,Sickle cell anemia ,Erythrocyte Inclusions ,medicine.anatomical_structure ,Hemoglobinopathy ,Liver ,Erythrocyte Count ,Female ,business ,Biomarkers - Abstract
We evaluated spleen function in 193 children with sickle cell anemia 8 to 18 months of age by 99mTc sulfur-colloid liver-spleen scan and correlated results with clinical and laboratory parameters, including 2 splenic biomarkers: pitted cell counts (PIT) and quantitative Howell-Jolly bodies (HJB) enumerated by flow cytometry. Loss of splenic function began before 12 months of age in 86% of infants in association with lower total or fetal hemoglobin and higher white blood cell or reticulocyte counts, reinforcing the need for early diagnosis and diligent preventive care. PIT and HJB correlated well with each other and liver-spleen scan results. Previously described biomarker threshold values did define patients with abnormal splenic function, but our data suggest that normal spleen function is better predicted by PIT of ≤ 1.2% or HJB ≤ 55/106 red blood cells and absent function by PIT ≥ 4.5% or HJB ≥ 665/106. HJB is methodologically advantageous compared with PIT, but both are valid biomarkers of splenic function. This trial was registered at www.clinicaltrials.gov as #NCT00006400. more...
- Published
- 2011
- Full Text
- View/download PDF
26. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial
- Author
-
Carlo Brugnara, Karen Kesler, Lynne Neumayr, Winfred C. Wang, Zora R. Rogers, Kim Smith-Whitley, Karen Kalinyak, Lynn W. Wynn, Asif Qureshi, David H.K. Chui, Cathie Snyder, Clark Brown, Marilyn J. Telen, Mardee Delahunty, Martin H. Steinberg, Carolyn Bigelow, and Rob Woolson more...
- Subjects
Hemolytic anemia ,medicine.medical_specialty ,business.industry ,medicine.drug_class ,Hematology ,medicine.disease ,Placebo ,Gastroenterology ,Antimetabolite ,Sickle cell anemia ,law.invention ,Surgery ,Clinical trial ,Hydroxycarbamide ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,business ,medicine.drug - Abstract
In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted. more...
- Published
- 2011
- Full Text
- View/download PDF
27. Advantages of isovolemic hemodilution-red cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients
- Author
-
Ravindra Sarode, Karen Matevosyan, Cynthia J. Rutherford, James D. Burner, and Zora R. Rogers
- Subjects
medicine.medical_specialty ,Red Cell ,business.industry ,Anemia ,Blood volume ,Hematology ,General Medicine ,medicine.disease ,Sickle cell anemia ,Surgery ,Apheresis ,medicine ,cardiovascular diseases ,Chelation therapy ,business ,Adverse effect ,Stroke - Abstract
Chronic simple hypertransfusion (every 3 to 4 weeks) effectively prevents secondary stroke in children with sickle cell anemia but leads to iron overload despite chelation therapy. Conventional red blood cell exchange (C-RBCx) has advantages over simple transfusion: no net iron gain and less frequent hospital visits. However, C-RBCx requires more red blood cell units, an apheresis instrument and skilled personnel; it is also more expensive. We developed a modified procedure where isovolemic hemodilution precedes RBCx (IHD-RBCx) to decrease RBC units required and to increase the interval between procedures. Twenty patients underwent IHD-RBCx over a period of 7 years. IHD-RBCx required 11% fewer RBC units and increased inter-procedure interval from 37 to 53 days compared to C-RBCx. The median number of annual procedures decreased from 9.8 to 7.0 per patient, resulting in estimated savings of more than $4.5 million over 10 years for 20 patients while providing improved care. Five patients have discontinued chelation therapy; three while on C-RBCx and two while on IHD-RBCx. No adverse events occurred related to the isovolemic hemodilution phase and no patients had recurrent stroke. IHD-RBCx is a safe, efficient, and cost effective therapy for secondary prevention of stroke in patients with sickle cell anemia. more...
- Published
- 2011
- Full Text
- View/download PDF
28. Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
- Author
-
Barbara Gruner, Kelly Walkovich, Christine M. Knoll, Mohammad Lufti Lababidi, Jason E. Farrar, Anupama Narla, Helge Hartung, Zora R. Rogers, Waseem Alhushki, Evangelia Atsidaftos, Ellen Muir, Bertil Glader, Arun R Panigrahi, Colin A. Sieff, Jeffrey M. Lipton, Adrianna Vlachos, and Grzegorz Nalepa more...
- Subjects
medicine.medical_specialty ,Blood transfusion ,Red Cell ,Anemia ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,030204 cardiovascular system & hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Pancytopenia ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Liver function ,Diamond–Blackfan anemia ,business - Abstract
Diamond Blackfan anemia (DBA) is a rare, inherited bone marrow failure syndrome characterized by anemia, congenital anomalies and a predisposition to cancer. The patients usually present during infancy or early childhood, but can also present in adulthood. In the majority of cases DBA is due to a mutation in a small or large ribosomal protein (RP) subunit leading to RP haploinsufficiency. The only treatments for the anemia of DBA are red cell transfusions (accompanied by iron chelation), oral corticosteroid therapy or stem cell transplantation. Pospisilova et al. (Haematologica 2007; 92(5):e66-67) reported one complete and two partial erythroid responses after the use of the branched chain amino acid L-leucine in 6 select patients. In skeletal muscle, leucine supplementation can upregulate components of the protein synthetic machinery, including ribosomal proteins, promoting protein translation. Mouse and fish models of DBA respond with amelioration of anemia to L-leucine. We therefore proposed to study the effect of L-leucine on transfusion dependence and growth in subjects with DBA. Methods: The primary objectives were to determine the feasibility of administering L-leucine in subjects with DBA who are red cell transfusion-dependent and to determine the efficacy of L-leucine to produce a hematologic and growth response. The secondary objective was to determine the safety profile of L-leucine. Twelve study sites were involved in this multi-center, Phase I/II study with an anticipated accrual of 50 subjects. A dose of 700 mg/M2 orally three times per day for 9 months was used. Inclusion criteria included age > 2 years, the diagnosis of DBA and transfusion dependence with adequate kidney and liver function. Response was evaluated at 9 months with Complete Response (CR) defined as no further transfusions required and Hb >9; Partial Response (PR): Hb < 9 gm/dL with an increase in reticulocyte count and transfusion interval; and No Response (NR): no change in transfusion needs, Hb or reticulocyte count . Growth percentiles were evaluated at baseline and at completion of 9 months of treatment and the growth velocity change was calculated. Results: The study opened July 2014 and closed February 2017; 55 subjects were consented; 12 were screen failures; 43 subjects were evaluable. There were 21 males; the median age was 9 years 1 month (2 years 5 months - 46 years 1 month). There were no untoward side effects experienced by any subject that were attributable to the L-leucine. Two subjects had an erythroid CR and 1 subject had a PR. The CRs occurred at 1 month and 3 months after start of L-leucine. The subject with PR had an elevated reticulocyte count but was not able to maintain a Hb >9 gm/dL without a transfusion and thus was not transfusion independent. Of the 30 subjects with growth potential who received L-leucine 10 experienced a positive growth velocity change at 9 months of therapy compared to baseline. At a median age of 7.5 years, the mean pre-leucine height percentile was 27 +/- 17.9 and the post-leucine height percentile was 35 +/- 19.9 (p Conclusions: The administration of L-leucine is safe. L-leucine administration resulted in an erythroid response in 7% of subjects and an increased growth velocity in 33% of growing subjects. Based upon extrapolation from animal models, it is likely that this dose was suboptimal. We hypothesize that higher doses of L-leucine will lead to hematologic responses in more subjects who are transfusion dependent. The potential benefit of added growth in children with DBA may improve final adult height. Disclosures Glader: Agios: Consultancy, Research Funding. more...
- Published
- 2018
- Full Text
- View/download PDF
29. Health-related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium
- Author
-
Kim Smith-Whitley, Petra LeBeau, Winfred C. Wang, Marsha McMurray, Seungshin Rhee, Zora R. Rogers, Susan Lieff, and Carlton Dampier
- Subjects
Male ,Parents ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Pain ,Anemia, Sickle Cell ,Disease ,Article ,Quality of life ,Surveys and Questionnaires ,Activities of Daily Living ,Humans ,Medicine ,Child ,Fatigue ,Health related quality of life ,business.industry ,Small sample ,Hematology ,Asthma ,humanities ,Hospitalization ,Clinical trial ,Oncology ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Quality of Life ,Female ,business - Abstract
Pediatric health-related quality of life (HRQOL) questionnaires have been validated in children with sickle cell disease (SCD), but small sample sizes in these studies have limited clinical comparisons. We used the baseline clinical data from the Collaborative Data (C-Data) Project of the Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium to perform a detailed, descriptive study of HRQOL using the PedsQL version 4.0 generic core and fatigue scales.Retrospective clinical data were obtained via medical record abstraction. Staff-administered health history, psychosocial, and health behavior interviews were completed by a parent or guardian. PedsQL forms were completed separately by the child and a parent/guardian.The study enrolled 1,772 subjects (53% boys) with a mean age of 9.6 years (SD 4.7). SS or Sbeta(0) thalassemia occurred in 68% and 32% had SC or Sbeta(+) thalassemia. The occurrences of pain, priapism, avascular necrosis of hips/shoulders (AVN), or asthma were the most common complications/conditions reported. Multiple regression models controlling for hemoglobinopathies, gender, and age suggested that parent reports of physical functioning and sleep/rest fatigue declined in response to pain or AVN, while school functioning scales declined in response to pain or asthma. Sickle pain, and to a lesser extent asthma, negatively influenced child reports on almost all functioning and fatigue scales.While longitudinal studies will be necessary to determine sensitivity to change, the current study suggests the potential utility of several PedsQL HRQOL scales as patient-reported outcome measures for observational or interventional treatment studies of children and adolescents with SCD. more...
- Published
- 2010
- Full Text
- View/download PDF
30. Improved survival of children and adolescents with sickle cell disease
- Author
-
Timothy L. McCavit, Charles T. Quinn, George R. Buchanan, and Zora R. Rogers
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Adolescent ,Clinical Trials and Observations ,Anemia ,Immunology ,Anemia, Sickle Cell ,Biochemistry ,Sepsis ,medicine ,Humans ,Young adult ,Child ,Survival rate ,Quality of Health Care ,Cause of death ,business.industry ,Incidence ,Incidence (epidemiology) ,Age Factors ,Infant, Newborn ,Infant ,Cell Biology ,Hematology ,medicine.disease ,Texas ,Sickle cell anemia ,Acute chest syndrome ,Survival Rate ,Child, Preschool ,Cohort ,Female ,business ,Follow-Up Studies - Abstract
The survival of young children with sickle cell disease (SCD) has improved, but less is known about older children and adolescents. We studied the Dallas Newborn Cohort (DNC) to estimate contemporary 18-year survival for newborns with SCD and document changes in the causes and ages of death over time. We also explored whether improvements in the quality of medical care were temporally associated with survival. The DNC now includes 940 subjects with 8857 patient-years of follow-up. Most children with sickle cell anemia (93.9%) and nearly all children with milder forms of SCD (98.4%) now live to become adults. The incidence of death and the pattern of mortality changed over the duration of the cohort. Sepsis is no longer the leading cause of death. All the recent deaths in the cohort occurred in patients 18 years or older, most shortly after the transition to adult care. Quality of care in the DNC has improved over time, with significantly more timely initial visits and preventive interventions for young children. In summary, most children with SCD now survive the childhood years, but young adults who transition to adult medical care are at high risk for early death. more...
- Published
- 2010
- Full Text
- View/download PDF
31. Hemophagocytic lymphohistiocytosis in Texas: Observations on ethnicity and race
- Author
-
J. Allyson Niece, Anne-Marie R Langevin, Naveed Ahmad, Zora R. Rogers, and Kenneth L. McClain
- Subjects
Hemophagocytic lymphohistiocytosis ,Pediatrics ,medicine.medical_specialty ,business.industry ,Ethnic group ,Retrospective cohort study ,Hematology ,Disease ,medicine.disease ,Histiocytosis ,Race (biology) ,Oncology ,Pediatrics, Perinatology and Child Health ,medicine ,Fatal disease ,business ,Epstein–Barr virus infection - Abstract
Background Early recognition and aggressive treatment of hemophagocytic lymphohistiocytosis (HLH) has changed a uniformly fatal disease to one 55% survive. We examined the diagnosis and treatment of pediatric patients with HLH from the three largest academic medical centers in Texas for information on modern non-study treatment and survival. In contrast with previously reported series, the racial and ethnic composition of Texas provided a unique opportunity to evaluate the impact of race and ethnicity on survival with HLH. Procedure A retrospective chart review of local oncology and pathology databases identified 70 patients with HLH from 1992 to 2007. Median age was 1.8 years (range 0.1-16.5 years) and 43% were Latino. Results We identified 70 patients with an overall survival of 67% after a median follow-up of 3 months (range 1-139 months). Twenty patients (29%) underwent stem cell transplant (SCT). Seven patients (18%) had mutations in the Perforin, Munc 13-4, or Syntaxin-11 genes, consistent with primary disease. Calculated cross-sectional prevalence of HLH in Texas from our study is 1 in 100,000 children. The effect of Latino ethnicity on survival was not statistically significant. Conclusion HLH is a rare but potentially treatable illness with modern aggressive therapy. Though treatment is more standardized for HLH, the role of race and ethnicity as risk factors for development of disease and impact on outcome may warrant further investigation. more...
- Published
- 2009
- Full Text
- View/download PDF
32. Acute silent cerebral infarction in children with sickle cell anemia
- Author
-
Charles T. Quinn, Zora R. Rogers, Michael M. Dowling, and George R. Buchanan
- Subjects
medicine.medical_specialty ,business.industry ,Cerebral infarction ,Anemia ,Hematology ,medicine.disease ,Sickle cell anemia ,Diffusion-Weighted Magnetic Resonance Imaging ,Surgery ,Neurologic injury ,Blood cancer ,Oncology ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Cardiology ,Focal neurologic deficits ,business ,Stroke - Abstract
Silent cerebral infarctions (SCI) occur in up to 35% of children with sickle cell anemia (HbSS) but are rarely recognized during the initial 10–14 days when diffusion weighted magnetic resonance imaging (MRI) can differentiate acute infarctions from remote events. We report acute SCI in seven children with HbSS who had areas of restricted diffusion on MRI without persistent focal neurologic deficits. Four had acute SCI identified following acute anemic events. Our observations suggest that SCI are detectible in the acute phase, present with subtle neurologic symptoms, result in permanent neurologic injury, and may be caused by acute anemic events. Pediatr Blood Cancer 2010;54:461–464. © 2009 Wiley-Liss, Inc. more...
- Published
- 2009
- Full Text
- View/download PDF
33. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trial
- Author
-
Robert J. Adams, Judy Luden, R. Clark Brown, Renee C. Rees, Winfred C. Wang, Zora R. Rogers, Scott T. Miller, Courtney D. Thornburg, Steven G. Pavlakis, Ram Kalpatthi, Xiangke Huang, James F. Casella, and Rathi V. Iyer more...
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Anemia ,Hematology ,Baseline data ,medicine.disease ,Sickle cell anemia ,Transcranial Doppler ultrasonography ,Clinical trial ,Blood cancer ,Oncology ,Pediatrics, Perinatology and Child Health ,Cohort ,cardiovascular system ,Medicine ,business ,Stroke - Abstract
Background Transcranial Doppler ultrasonography (TCD) is used to predict stroke risk in children with sickle cell anemia (SCA), but has not been adequately studied in children under age 2 years. Procedure TCD was performed on infants with SCA enrolled in the BABY HUG trial. Subjects were 7–17 months of age (mean 12.6 months). TCD examinations were successfully performed in 94% of subjects (n = 192). Results No patient had an abnormal TCD as defined in the older child (time averaged maximum mean TAMM velocity ≥200 cm/sec) and only four subjects (2%) had velocities in the conditional range (170–199 cm/sec). TCD velocities were inversely related to hemoglobin (Hb) concentration and directly related to increasing age. Conclusion Determination of whether the TCD values in this very young cohort of infants with SCA can be used to predict stroke risk later in childhood will require analysis of exit TCD's and long-term follow-up, which is ongoing (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:256–259. © 2009 Wiley-Liss, Inc. more...
- Published
- 2009
- Full Text
- View/download PDF
34. The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design
- Author
-
Winfred C. Wang, Sohail Rana, Russell E. Ware, Zora R. Rogers, Thomas H. Howard, Julio C. Barredo, James F. Casella, Bruce W. Thompson, Lori R. Luck, Myron A. Waclawiw, Lori Luchtman-Jones, Renee C. Rees, R. Clark Brown, Scott T. Miller, Rathi V. Iyer, Courtney D. Thornburg, Ram Kalpatthi, and Sharada A. Sarnaik more...
- Subjects
medicine.medical_specialty ,Pediatrics ,Blinding ,business.industry ,Alternative medicine ,Hematology ,medicine.disease ,Sickle cell anemia ,Clinical trial ,Oncology ,Pediatrics, Perinatology and Child Health ,Toxicity ,medicine ,Clinical endpoint ,Clinical significance ,Clinical efficacy ,business - Abstract
Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso-occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of the drug at an early age. BABY HUG is a randomized, double-blind placebo-controlled trial to test whether treating young children ages 9–17 months at entry with a liquid preparation of hydroxyurea (20 mg/kg/day for 2 years) can decrease organ damage in the kidneys and spleen by at least 50%. Creation of BABY HUG entailed unique challenges and opportunities. Although protection of brain function might be considered a more compelling endpoint, preservation of spleen and renal function has clinical relevance, and significant treatment effects might be discernable within the mandated sample size of 200. Concerns about unanticipated severe toxicity and burdensome testing and monitoring requirements were addressed in part by an internal Feasibility and Safety Pilot Study, the successful completion of which was required prior to enrolling a larger number of children on the protocol. Concerns over recruitment of potentially vulnerable subjects were allayed by inclusion of a research subject advocate, or ombudsman. Finally, maintenance of blinding of research personnel was aided by inclusion of an unblinded primary endpoint person, charged with transmitting endpoint data and monitoring blood work locally for toxicity (ClinicalTrials.gov number, NCT00006400). Pediatr Blood Cancer 2010;54:250–255. © 2009 Wiley-Liss, Inc. more...
- Published
- 2009
- Full Text
- View/download PDF
35. Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis
- Author
-
George R. Buchanan, Zora R. Rogers, Lynn Clark, Josh Koch, Renee C.B. Manworren, and Charles T. Quinn
- Subjects
Male ,Narcotics ,Adolescent ,Vomiting ,Nausea ,Visual analogue scale ,Narcotic Antagonists ,Analgesic ,Pain ,Pilot Projects ,Anemia, Sickle Cell ,(+)-Naloxone ,Article ,medicine ,Humans ,Child ,Infusions, Intravenous ,Adverse effect ,Pain Measurement ,Morphine ,Naloxone ,business.industry ,Pruritus ,Hematology ,medicine.disease ,Hyperalgesia ,Anesthesia ,Itching ,Drug Therapy, Combination ,Female ,medicine.symptom ,business ,Vaso-occlusive crisis ,medicine.drug - Abstract
Patients with sickle cell disease experience painful crises that often require hospitalization for a continuous infusion of morphine that may cause significant pruritus. We conducted a pilot study to determine the feasibility of simultaneous continuous co-infusion of naloxone with morphine, test novel assessment instruments for pruritus, and explore whether pruritus could be reduced while maintaining effective analgesia. Patients with sickle cell disease and painful crisis requiring continuous infusion morphine received continuous co-infusion of naloxone at 0.25 (low dose) or 1.0 mcg/kg x hr (high dose). Pain scores were obtained using the FACES scale and a 100-mm visual analog scale (VAS). Itching was quantified by a modified VAS score. Evaluable data were obtained on 16 patients. Simultaneous co-infusion of naloxone and morphine was feasible, did not seem to reduce the analgesic efficacy of morphine, and was associated with no adverse effects. The high dose group reported a lower median "VAS worst itch" score than the low dose group (4.8 vs. 7.3, P = 0.08). Simultaneous continuous infusion of naloxone with morphine in pediatric patients with sickle cell disease and pain crisis was feasible and well tolerated. A quantitative pruritus score allowed us to systematically measure pruritus. Further evaluation by randomized, placebo-controlled study of 1 mcg/kg x hr naloxone in this setting is required. more...
- Published
- 2008
- Full Text
- View/download PDF
36. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort
- Author
-
Naveed Ahmad, Charles T. Quinn, George R. Buchanan, Zora R. Rogers, Elizabeth P. Shull, and Nancy J. Lee
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Clinical Trials and Observations ,Anemia ,Immunology ,Pain ,Anemia, Sickle Cell ,Models, Biological ,Biochemistry ,Predictive Value of Tests ,Risk Factors ,medicine ,Humans ,Child ,Adverse effect ,Stroke ,Retrospective Studies ,business.industry ,Infant ,Retrospective cohort study ,Cell Biology ,Hematology ,medicine.disease ,Sickle cell anemia ,Acute chest syndrome ,Child, Preschool ,Cohort ,Female ,business ,Follow-Up Studies ,Cohort study - Abstract
The Cooperative Study of Sickle Cell Disease reported that dactylitis, severe anemia, and leukocytosis in very young children with sickle cell disease (SCD) increased the risk of later adverse outcomes, including death, stroke, frequent pain, and recurrent acute chest syndrome. This model has not been validated in other cohorts. We evaluated its performance in the Dallas Newborn Cohort, a newborn inception cohort of children with SCD. We studied 168 children (55% male, 97% sickle cell anemia) with a mean follow-up of 7.1 years who provided 1188 patient-years of observation. Of the 23 (13.7%) subjects who experienced adverse events, 2 (1.2%) died, 14 (8.3%) had a stroke, 4 (2.4%) had frequent pain, and 3 (1.8%) had recurrent acute chest syndrome. No relationship existed between early clinical predictors and later adverse outcomes, with the possible exception of leukocyte count. Most subjects who experienced adverse events were predicted to be at low risk for those events. No subject who was predicted to be at high risk actually experienced an adverse outcome. The sensitivity of the model did not rise above 20% until specificity fell below 60%. We suggest that this model not be used as a criterion to initiate early interventions for SCD. more...
- Published
- 2008
- Full Text
- View/download PDF
37. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia
- Author
-
Thomas V. Adamkiewicz, B. Sleight, Peter A. Lane, Keith M. Sullivan, A. Haight, Barry Eggleston, Lewis L. Hsu, N. Kamani, John T. Horan, Roger Giller, Rupa Redding-Lallinger, Alexis A. Thompson, T. B. Moore, George R. Buchanan, J. E. Levine, J. E. Sanders, S. Donfield, Sandie Edwards, David A. Margolis, R. Dickerhoff, S. A. Feig, J. P. Scott, Mark C. Walters, S. C. Davies, Zora R. Rogers, Melinda Patience, I. A.G. Roberts, and K. Ohene-Frempong more...
- Subjects
Male ,Hemolytic anemia ,Oncology ,Aging ,medicine.medical_specialty ,Anemia ,Anemia, Sickle Cell ,Growth ,Weight Gain ,Antisickling Agents ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Hydroxyurea ,Child ,Adverse effect ,Bone Marrow Transplantation ,Hematology ,business.industry ,Age Factors ,medicine.disease ,Body Height ,Sickle cell anemia ,Transplantation ,surgical procedures, operative ,medicine.anatomical_structure ,Hemoglobinopathy ,Child, Preschool ,Immunology ,Female ,Bone marrow ,business ,Follow-Up Studies - Abstract
Although haematopoietic cell transplantation (HCT) is curative for sickle cell anaemia (SCA), concerns about its short- and long-term toxicities limit its application. A potential toxicity is an adverse effect on growth. To identify an HCT growth effect, serial height and weight measurements from 53 children and adolescents with SCA after receiving a transplant were compared to historical controls. Hierarchical Linear Models for longitudinal data were used for analysis. In general growth was not impaired by HCT for SCA in young children; however, diminished growth may occur if HCT is carried out near or during the adolescent growth spurt. more...
- Published
- 2007
- Full Text
- View/download PDF
38. Effects of hydroxyurea treatment for patients with hemoglobin SC disease
- Author
-
Lori, Luchtman-Jones, Sara, Pressel, Lee, Hilliard, R Clark, Brown, Mary G, Smith, Alexis A, Thompson, Margaret T, Lee, Jennifer, Rothman, Zora R, Rogers, William, Owen, Hamayun, Imran, Courtney, Thornburg, Janet L, Kwiatkowski, Banu, Aygun, Stephen, Nelson, Carla, Roberts, Cynthia, Gauger, Connie, Piccone, Theodosia, Kalfa, Ofelia, Alvarez, Kathryn, Hassell, Barry R, Davis, and Russell E, Ware more...
- Subjects
Male ,Treatment Outcome ,Adolescent ,Antisickling Agents ,Humans ,Hydroxyurea ,Female ,Anemia, Sickle Cell ,Child ,Retrospective Studies - Abstract
Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA), which includes HbSS and HbS/β(0) -thalassemia genotypes, many patients with HbSC experience severe disease complications, including vaso-occlusive pain, acute chest syndrome, avascular necrosis, retinopathy, and poor quality of life. Fully 20 years after the clinical and laboratory efficacy of hydroxyurea was proven in adult SCA patients, the safety and utility of hydroxyurea treatment for HbSC patients remain unclear. Recent NHLBI evidence-based guidelines highlight this as a critical knowledge gap, noting HbSC accounts for ∼30% of sickle cell patients within the United States. To date, only 5 publications have reported short-term, incomplete, or conflicting laboratory and clinical outcomes of hydroxyurea treatment in a total of 71 adults and children with HbSC. We now report on a cohort of 133 adult and pediatric HbSC patients who received hydroxyurea, typically for recurrent vaso-occlusive pain. Hydroxyurea treatment was associated with a stable hemoglobin concentration; increased fetal hemoglobin (HbF) and mean corpuscular volume (MCV); and reduced white blood cell count (WBC), absolute neutrophil count (ANC), and absolute reticulocyte count (ARC). Reversible cytopenias occurred in 22% of patients, primarily neutropenia and thrombocytopenia. Painful events were reduced with hydroxyurea, more in patients15 years old. These multicenter data support the safety and potentially salutary effects of hydroxyurea treatment for HbSC disease; however, a multicenter, placebo-controlled, Phase 3 clinical trial is needed to determine if hydroxyurea therapy has efficacy for patients with HbSC disease. more...
- Published
- 2015
39. Guidelines for the Standard Monitoring of Patients with Thalassemia: Report of the Thalassemia Longitudinal Cohort
- Author
-
Alexis A. Thompson, Zora R. Rogers, Janet L. Kwiatkowski, Maria G. Vogiatzi, Venée N. Tubman, Ellen B. Fung, and Ellis J. Neufeld
- Subjects
Pediatrics ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Blood transfusion ,Thalassemia ,medicine.medical_treatment ,MEDLINE ,Article ,hemic and lymphatic diseases ,medicine ,Humans ,Blood Transfusion ,Longitudinal Studies ,Longitudinal cohort ,Monitoring, Physiologic ,business.industry ,Extramural ,Hematology ,medicine.disease ,Hemoglobinopathies ,Oncology ,Pediatrics, Perinatology and Child Health ,Life expectancy ,Transfusion therapy ,business - Abstract
Chronic transfusion therapy has played a central role in extending life expectancy for patients with hemoglobinopathies such as thalassemia. However, this life-saving therapy is associated with numerous complications that now comprise the bulk of management considerations for patients with thalassemia. This review reports on the experience of the Thalassemia Longitudinal Cohort and reviews available literature to establish guidelines for the management of patients with thalassemia. more...
- Published
- 2015
40. Review: clinical transfusion management in sickle cell disease
- Author
-
Zora R. Rogers
- Subjects
medicine.medical_specialty ,Pregnancy ,business.industry ,Anemia ,MEDLINE ,Hematology ,General Medicine ,Disease ,medicine.disease ,medicine ,Immunology and Allergy ,Transfusion management ,Disease management (health) ,Intensive care medicine ,business ,Risk management - Published
- 2006
- Full Text
- View/download PDF
41. Priapism in Sickle Cell Disease
- Author
-
Zora R. Rogers
- Subjects
Male ,medicine.medical_specialty ,Pediatrics ,business.industry ,Priapism ,Anemia, Sickle Cell ,Comorbidity ,Hematology ,Disease ,urologic and male genital diseases ,medicine.disease ,Sickle cell anemia ,Surgery ,medicine.anatomical_structure ,Oncology ,Penile injury ,Epidemiology ,medicine ,Humans ,Complication ,business ,Penis - Abstract
Priapism, an unwanted painful erection of the penis, is a little discussed but common complication of sickle cell disease. What is known about the prevalence of priapism, efficacy of management approaches, and outcome is drawn primarily from retrospective and single-center reports. Priapism occurs in two patterns: prolonged and stuttering (ie, recurrent brief episodes that resolve spontaneously). If priapism persists for 4 hours or more without detumescence, the patient is at risk for irreversible ischemic penile injury, which may terminate in fibrosis and impotence. Large multicenter studies examining the epidemiology and current treatments and well-organized trials of novel therapies are urgently needed for patients who have sickle cell disease and priapism. more...
- Published
- 2005
- Full Text
- View/download PDF
42. Survival of children with sickle cell disease
- Author
-
Charles T. Quinn, Zora R. Rogers, and George R. Buchanan
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adolescent ,Anemia ,Thalassemia ,Immunology ,Anemia, Sickle Cell ,Penicillins ,Biochemistry ,Article ,Cohort Studies ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Child ,Stroke ,Survival analysis ,business.industry ,Incidence ,Incidence (epidemiology) ,beta-Thalassemia ,Infant, Newborn ,Infant ,Beta thalassemia ,Bacterial Infections ,Cell Biology ,Hematology ,medicine.disease ,Survival Analysis ,Texas ,Sickle cell anemia ,Surgery ,Child, Preschool ,Female ,business ,Cohort study - Abstract
Contemporary survival data are not available for children with sickle cell disease (SCD). The few previous childhood SCD cohort studies do not reflect the benefits of modern therapy. We defined an inception cohort of newborns with sickle cell anemia (SS), sickle-beta degrees -thalassemia (S beta degrees ), sickle-hemoglobin C disease (SC), or sickle-beta(+)-thalassemia (Sbeta(+)) who were identified by newborn screening and followed for up to 18 years. The incidence of death and stroke were calculated. Overall survival, SCD-related survival (considering only SCD-related deaths), and strokefree survival were determined. The 711 subjects provided 5648 patient-years of observation. Twenty-five subjects died; mean age at death was 5.6 years. Five patients died from infection. Thirty had at least one stroke. Among SS and Sbeta degrees subjects (n = 448), the overall rates of death and stroke were 0.59 and 0.85/100 patient-years. Survival analysis of SS and Sbeta degrees subjects predicted the cumulative overall, SCD-related, and stroke-free survival to be 85.6%, 93.6%, and 88.5% by 18 years of age. No SCD-related deaths or strokes occurred in SC or Sbeta(+) subjects (n = 263). Childhood mortality from SCD is decreasing, the mean age at death is increasing, and a smaller proportion of deaths are from infection. more...
- Published
- 2004
- Full Text
- View/download PDF
43. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities
- Author
-
Lisa Kuisel, Jeff Olson, Stephen C. Nelson, Cynthia Gauger, Hamayun Imran, Antonella Farrell, Mary DeBarr, Elizabeth Yang, Scott T. Miller, Lisa Wruck, Meredith Anderson, Alexis A. Thompson, Charles Daeschner, Sharon A. Singh, Regina McCollum, Courtney D. Thornburg, Williams Patrice Williams, Matthew M. Heeney, Janet L. Kwiatkowski, Natalie Sommerville-Brooks, Alvarez Ofelia Alvarez, Jeanine Dumas, Katie Bianchi, Eileen N. Hansbury, Martha Brown, Stephanie Farias, Zora R. Rogers, Manuella Merelles-Pulcinni, Isaac Odame, Sharada A. Sarnaik, Sheronda Brown, Mary Murphy, Lakshmanan Krishnamurti, Rathi V. Iyer, Ronald W. Helms, Kathy Rey, Bogdan Dinu, Cynthia D. Brown, Ramamoorthy Nagasubramanian, Brigitta U. Mueller, Nagina Parmar, Kamar Godder, Clark Brown, Lori Luchtman-Jones, Brian W. Berman, Stephanie Durggin, Lee Hilliard, Michelle Neier, Sherron M. Jackson, Russell E. Ware, Banu Aygun, William H. Schultz, William Owen, Mary T. Walker, Kusum Viswanathan, Margaret T. Lee, Betsy Record, Leah Adix, and Jennifer Newlin more...
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Anemia ,medicine.medical_treatment ,Exchange transfusion ,Hematology ,medicine.disease ,Cerebrovascular Circulation ,Sickle cell anemia ,Clinical trial ,Multicenter study ,Medicine ,Ultrasonography ,business ,Stroke - Published
- 2012
- Full Text
- View/download PDF
44. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia
- Author
-
Jin He, Kathy Rey, Scott T. Miller, Winfred C. Wang, Zora R. Rogers, Jonathan M. Flanagan, Billie Fish, and Russell E. Ware
- Subjects
Pediatrics ,medicine.medical_specialty ,Anemia ,business.industry ,Hematology ,Drug overdose ,medicine.disease ,Sickle cell anemia ,Acute chest syndrome ,Hydroxycarbamide ,Clinical trial ,Oncology ,Accidental ,Pediatrics, Perinatology and Child Health ,Toxicity ,medicine ,business ,medicine.drug - Abstract
The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612 mg/kg body weight). Despite a serum level of 7,756 µM 4 hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400). more...
- Published
- 2011
- Full Text
- View/download PDF
45. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia
- Author
-
Lynn W. Wynn, Winfred C. Wang, Russell E. Ware, J. Paul Scott, Peter A. Lane, and Zora R. Rogers
- Subjects
Male ,Hemolytic anemia ,Pediatrics ,medicine.medical_specialty ,Time Factors ,Anemia ,Thalassemia ,Pilot Projects ,Anemia, Sickle Cell ,Neutropenia ,Hydroxycarbamide ,Hemoglobins ,Antisickling Agents ,hemic and lymphatic diseases ,medicine ,Humans ,Hydroxyurea ,Splenic Diseases ,business.industry ,Organ dysfunction ,Age Factors ,Infant ,medicine.disease ,Hematologic Diseases ,Sickle cell anemia ,Blood Cell Count ,Hemoglobinopathy ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Feasibility Studies ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Objective: Hydroxyurea improves hematologic values and decreases vaso-occlusive complications in adults and children with sickle cell anemia (SCA), but has not been tested in infants before the onset of chronic organ dysfunction. We conducted a collaborative pilot trial of hydroxyurea in infants with SCA to assess its (1) feasibility of administration, (2) toxicity, (3) hematologic effects, and (4) effect on spleen function. Study design: Patients with hemoglobin (Hb) SS or Sβ0 thalassemia (n = 28, median age 15 months) received hydroxyurea for 2 years at 20 mg/kg/day. Hydroxyurea was temporarily discontinued for predefined toxicity. Results: Seven patients exited the study early: five for noncompliance or refusal to continue, one for mild stroke, and one for fatal splenic sequestration. The predominant toxicity was transient neutropenia, which was usually associated with a viral-like illness. After 2 years of treatment, mean Hb level = 8.8 g/dL and Hb F = 20.3%, both higher than predicted age-specific levels. Radionuclide splenic uptake was absent in 47% of patients at study completion, compared with predicted functional asplenia in 80% of the patients. Conclusions: Hydroxyurea therapy for infants with SCA is feasible and well tolerated, has hematologic efficacy, and may delay functional asplenia. The potential for hydroxyurea to preserve organ function in SCA should be further evaluated. (J Pediatr 2001;139:790–6) more...
- Published
- 2001
- Full Text
- View/download PDF
46. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism
- Author
-
David H. Ewalt, Joe Don Cavender, Zora R. Rogers, Elpis Mantadakis, and George R. Buchanan
- Subjects
Chemotherapy ,medicine.medical_specialty ,business.industry ,Anemia ,medicine.medical_treatment ,Immunology ,Priapism ,Therapeutic irrigation ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Sickle cell anemia ,Surgery ,Pulmonary aspiration ,Anesthesia ,medicine ,Local anesthesia ,business ,Complication - Abstract
The optimal management of prolonged priapism for patients with sickle cell anemia (SCA) has not been established. We prospectively studied in an outpatient setting the efficacy and safety of a procedure that employs aspiration of blood from the corpora cavernosa and irrigation with a dilute epinephrine solution under local anesthesia to relieve priapism in young patients with SCA. If hydration and analgesics failed to produce detumescence or if priapism had lasted >4 hours, the protocol was activated in the emergency room or clinic. Fifteen patients with homozygous SCA (Hb SS) were treated on 39 occasions; 10 patients were treated once, 1 patient twice, 2 patients 3 times, 1 patient 6 times, and 1 patient 15 times. Median age of patients at first treatment was 14.3 years (range, 3.9-18.3 years). The procedure was successful in producing immediate detumescence on 37 of 39 occasions (95% efficacy, 95% confidence intervals (CI): 81%-99%). No serious immediate or long-term side effects were observed. None of the patients who demonstrated detumescence required hospitalization. The 2 patients whose priapism persisted after aspiration and irrigation presented with episodes lasting >24 hours. All evaluable patients whose priapism resolved after aspiration and irrigation self-reported normal erectile function at a median of 40 months (range, 3-58 months) after the last procedure. Thus, aspiration of the corpora cavernosa followed by irrigation with dilute epinephrine is effective in producing immediate and sustained detumescence and should be the initial therapy employed for patients with SCA and prolonged priapism. (Blood, 2000; 95:78-82) more...
- Published
- 2000
- Full Text
- View/download PDF
47. Stroke in Sickle Cell Anemia: Alternative Etiologies
- Author
-
Charles T. Quinn, Janna M. Journeycake, Michael M. Dowling, and Zora R. Rogers
- Subjects
Hemolytic anemia ,medicine.medical_specialty ,business.industry ,Vascular disease ,medicine.disease ,Sickle cell anemia ,Surgery ,Hemoglobinopathy ,Developmental Neuroscience ,Neurology ,hemic and lymphatic diseases ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Cardiology ,Patent foramen ovale ,Etiology ,Pediatric stroke ,cardiovascular diseases ,Neurology (clinical) ,business ,Stroke - Abstract
Stroke is common in children with sickle cell anemia, but is rarely attributed to the traditional causes of stroke identified in other children. An 11-year-old girl with sickle cell anemia presented with severe headache and was found to have recurrent bilateral multifocal strokes in a cardioembolic pattern. Evaluation revealed the presence of a patent foramen ovale, antiphospholipid antibodies, and elevations in factor VIII and lipoprotein(a). Sickle cell anemia is itself a hypercoagulable state with potential for increased right heart pressures, both of which predispose to paradoxical embolization via right-to-left intracardiac shunting of emboli, thus causing stroke. The present case suggests that the more traditional etiologies for pediatric stroke may also cause stroke in children with sickle cell anemia. more...
- Published
- 2009
- Full Text
- View/download PDF
48. Prevalence of Priapism in Children and Adolescents With Sickle Cell Anemia
- Author
-
Joe Don Cavender, Zora R. Rogers, David H. Ewalt, Elpis Mantadakis, and George R. Buchanan
- Subjects
Pediatrics ,medicine.medical_specialty ,Anemia ,business.industry ,Thalassemia ,Priapism ,Hematology ,medicine.disease ,Sickle cell anemia ,Surgery ,Hemoglobinopathy ,Oncology ,El Niño ,Pediatrics, Perinatology and Child Health ,Epidemiology ,medicine ,Complication ,business - Abstract
A questionnaire survey was conducted of patients with homozygous sickle cell anemia (Hb SS) and sickle cell beta(0)-thalassemia (Hb S-beta(0)) between 5 and 20 years of age to determine the prevalence and characteristics (number of episodes, timing, duration, cause, or precipitating event) of priapism. Ninety-eight male patients or their parents were surveyed by the same male investigator using a structured verbal interview, which was modified according to the age of the patient. Ninety-four patients had Hb SS and four Hb S-beta(0) thalassemia. Eleven (11%) patients were known to have experienced priapism previously. In response to the questionnaire, 16 of the remaining 87 (18%) patients reported having had priapism on one or more occasions. The actuarial probability of experiencing priapism by 20 years of age was 89% (+/- 9%). The mean age at the initial episode was 12 years, the mean number of episodes per patient was 15.7 (median, 1; range, 1-100), and the mean duration of an episode was 125 minutes. Episodes typically occurred around 4:00 am, and 75% of the patients surveyed had at least one episode starting during sleep or upon awakening from sleep. The prevalence of priapism in children and adolescents with SCA is much higher than previously described. Since early intervention and treatment may prevent irreversible penile fibrosis and impotence, patients and parents should be educated about this complication in advance of its occurrence. more...
- Published
- 1999
- Full Text
- View/download PDF
49. Intravascular hemolysis following low dose daily rifampin
- Author
-
Zora R. Rogers, Scott Cameron, Cindy E. Neunert, and Geeta Paranjape
- Subjects
Male ,Methicillin-Resistant Staphylococcus aureus ,Anemia, Hemolytic ,Adolescent ,Anemia ,medicine.disease_cause ,Hemolysis ,Blood cancer ,polycyclic compounds ,medicine ,Humans ,Antibiotics, Antitubercular ,business.industry ,fungi ,Low dose ,Infant ,Hematology ,Staphylococcal Infections ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Intravascular hemolysis ,Oncology ,Staphylococcus aureus ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Drug Therapy, Combination ,Female ,Methicillin Resistance ,Rifampin ,business - Abstract
We report two pediatric patients with rifampin-induced hemolysis following treatment with low daily dose rifampin for methicillin-resistant Staphylococcus aureus (MRSA). With the increased use of rifampin to treat MRSA, physicians should be aware that patients receiving rifampin therapy are at risk for hemolysis, even at low daily doses. Pediatr Blood Cancer 2008;51:821–823. © 2008 Wiley-Liss, Inc. more...
- Published
- 2008
- Full Text
- View/download PDF
50. Beneficial Effect of Intravenous Dexamethasone in Children With Mild to Moderately Severe Acute Chest Syndrome Complicating Sickle Cell Disease
- Author
-
George R. Buchanan, Eric Sandler, Charles T. Quinn, Zora R. Rogers, Joan S. Reisch, and Juan Carlos Bernini
- Subjects
medicine.medical_specialty ,Blood transfusion ,Anemia ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Placebo ,Biochemistry ,Acute chest syndrome ,Sickle cell anemia ,Surgery ,Anesthesia ,medicine ,Corticosteroid ,Complication ,business ,Dexamethasone ,medicine.drug - Abstract
Acute chest syndrome (ACS) in patients with sickle cell disease (SCD) has historically been managed with oxygen, antibiotics, and blood transfusions. Recently high-dose corticosteroid therapy was shown to reduce the duration of hospitalization in children with SCD and vaso-occlusive crisis. Therefore, we chose to assess the use of glucocorticoids in ACS. We conducted a randomized, double-blind placebo-controlled trial to evaluate the efficacy and toxicity of intravenous dexamethasone (0.3 mg/kg every 12 hours × 4 doses) in children with SCD hospitalized with mild to moderately severe ACS. Forty-three evaluable episodes of ACS occurred in 38 children (median age, 6.7 years). Twenty-two patients received dexamethasone and 21 patients received placebo. There were no statistically significant differences in demographic, clinical, or laboratory characteristics between the two groups. Mean hospital stay was shorter in the dexamethasone-treated group (47 hours v 80 hours; P = .005). Dexamethasone therapy prevented clinical deterioration and reduced the need for blood transfusions (P < .001 and = .013, respectively). Mean duration of oxygen and analgesic therapy, number of opioid doses, and the duration of fever was also significantly reduced in the dexamethasone-treated patients. Of seven patients readmitted within 72 hours after discharge (six after dexamethasone; P = .095), only one had respiratory complications (P = 1.00). No side effects clearly related to dexamethasone were observed. In a stepwise multiple linear regression analysis, gender and previous episodes of ACS were the only variables that appeared to predict response to dexamethasone, as measured by lengh of hospital stay. Intravenous dexamethasone has a beneficial effect in children with SCD hospitalized with mild to moderately severe acute chest syndrome. Further study of this therapeutic modality is indicated.© 1998 by The American Society of Hematology. more...
- Published
- 1998
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.